How had Indian Pharma responded to the challenges brought on by the Covid19 crisis and the inability to connect with doctors and other Rx influencers?
Is it back to business-as-usual or have some companies learned from their mistakes and become digital savvy?
How will Indian Pharma cope with the possibility of another lockdown and meeting restrictions looming in view of the rising Omicron wave?
The life of the Pharma marketer has always been a juggling act (Two hands, Three balls, Endless Effect! A Lifetime of Performance) of managing multiple aspects with adept emotional and mental skill sets. All this, while trying to remain sane in a dynamic and confusing world. As the marketer takes time to make sense of his environment, he attempts to find answers to perennial marketing questions such as:
How is the campaign performing?
What are the new avenues to target customers?
Is the messaging, right?
Are the vendors on track with their deliverables?
Are metrics that we track insightful?
It is the twentieth anniversary of the new patent act in January 2025. The post-patent (P20) era is a story of resilience, determination, and charting a course that set global ambitions, a story of finding opportunity in adversity. It is a story for case studies in business schools, in international studies, in global health efforts.